Analysis of pediatric clinical drug trials for neuropsychiatric conditions

Related Experiment Video

Updated: May 11, 2026

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
10:02

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Srinivas Murthy1, Kenneth D Mandl, Florence Bourgeois

  • 1Department of Critical Care, Hospital for Sick Children, Toronto, ON, Canada. sgmurthy@gmail.com

Pediatrics
|May 8, 2013
PubMed

Insights

Pediatric neuropsychiatric drug research is limited, with few trials and even fewer drugs studied in children. This gap is most critical for conditions like depression and schizophrenia.

Area of Science:

  • Pediatric clinical pharmacology
  • Neuroscience research
  • Drug development and regulation

Background:

  • Neuropsychiatric conditions pose a significant and growing health challenge for children.
  • Many medications used for these conditions lack adequate testing and approval in pediatric populations, leading to widespread off-label use.

Purpose of the Study:

  • To quantify and characterize recent clinical research on neuropsychiatric drug use in children.
  • To assess the extent of Food and Drug Administration (FDA) approval and pediatric investigation for neuropsychiatric medications.

Main Methods:

  • Analysis of drug trials registered in ClinicalTrials.gov from 2006 to 2011 focusing on pediatric neuropsychiatric conditions.
  • Classification of trials based on FDA approval status in children and the proportion of drugs studied in pediatric populations.

Main Results:

  • Only 10% of all neuropsychiatric trials specifically focused on pediatric populations.
  • Of 303 drugs investigated in both adults and children, 90% lacked FDA approval for pediatric use, and 97% were unapproved for the specific indication studied.
  • A mere 19% of all available neuropsychiatric drugs were under investigation in pediatric trials, with antidepressants and antipsychotics being studied in only 8% of cases.

Conclusions:

  • Despite the increasing prevalence of pediatric neuropsychiatric disorders and a shortage of FDA-approved treatments, clinical research remains insufficient.
  • A small fraction of available neuropsychiatric drugs are being investigated in pediatric trials, highlighting a critical gap in evidence-based treatment for children.
  • This deficiency is particularly acute for pediatric depression and schizophrenia treatment research.
Abstract

Keywords:
neuropsychiatric conditionsoff-label drug usepediatric drug approvalpediatric research

More Related Videos

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...